Secondary Logo

Journal Logo

Original Articles: Hepatology and Nutrition

Relation Between Dietary Fat Intake Type and Serum Fatty Acid Status in Children With Cystic Fibrosis

Maqbool, Asim*; Schall, Joan I.*; Gallagher, Paul R.; Zemel, Babette S.*; Strandvik, Birgitta; Stallings, Virginia A.*

Author Information
Journal of Pediatric Gastroenterology and Nutrition: November 2012 - Volume 55 - Issue 5 - p 605-611
doi: 10.1097/MPG.0b013e3182618f33


Humans lack the enzymes to desaturate fatty acids (FAs) at the 3rd and 6th carbons from the methyl end of the molecule and are dependent on dietary sources to prevent essential fatty acid deficiency (EFAD). Linoleic acid (LA; 18:2ω6) and α-linolenic acid (ALA; 18:3ω3) are the ω6 and ω3 essential fatty acids (EFAs) in humans. LA is an important membrane constituent, and has multiple cellular structural and functional roles. EFAs are precursors to the long-chain polyunsaturated FA (LCPUFA), which by themselves and by their eicosanoid products are growth factors, signal substances, inflammatory mediators, and influence gene expression (1,2). EFAD and FA abnormalities have been described in patients with cystic fibrosis (CF) for >50 years (3), and many clinical symptoms are likely influenced by these abnormalities (4–6). The most frequently described FA abnormalities are decreased LA and docosahexaenoic acid (DHA; 22:6ω3) concentrations, and abnormal triene (Mead acid; 20:3ω9 acid):tetraene (arachidonic acid [AA]; 20:4ω6) (named T:T) ratio (7–9). LA concentration was associated with growth and pulmonary status in infants and children with CF (10–13).

Increased dietary fat intake was associated with improved survival, growth, and pulmonary function (14). Although the recent CF Nutrition Consensus Reports provide guidance regarding energy intake for children with CF, specific recommendations for type of dietary fat (eg, saturated fatty acid [SFA], monounsaturated fatty acid [MUFA] or polyunsaturated fatty acid [PUFA], total ω 3 polyunsaturated fatty acid [Tω3PUFA]) to support favorable profiles were not provided (15). The aim of the present study was to determine the relationship between type of dietary fat and serum FA status in preadolescent children with CF and pancreatic insufficiency (PI). These data may provide evidence for more dietary fat recommendations for CF Care Guidelines.


Children with CF and PI (ages 7–10 years) from 13 CF Centers participated in a study of nutritional status and progression of pulmonary disease. Cross-sectional data from the 12 months study visit are presented here. The rationale for selecting the present study time point was that dietary intake, serum FA concentrations, and anthropometric data were collected for the subjects with CF and for a contemporary comparison group of unaffected children.

The diagnoses of CF and PI were made by the home CF Center based on clinical symptoms, and duplicate quantitative pilocarpine iontophoresis sweat test, with chloride values of >60 mEq/L, and by genotype. PI was diagnosed by 3-day quantitative fecal fat collection and analysis of dietary intake, with <93% fat absorption (%CFA), and/or a stool trypsin value of <80 μg/L. Children were excluded if they had an forced expiratory volume at 1 second (FEV1) <40% predicted, significant liver disease, insulin-dependent diabetes mellitus, Burkholderia cepacia sputum colonization, or other medical conditions or use of medications known to affect growth. Healthy children of similar age, sex, and ethnic background, who participated in a bone health study at the Children's Hospital of Philadelphia (CHOP), served as comparison subjects. These healthy children were recruited from the CHOP primary care practices and the surrounding community. Exclusion criteria were the use of any medication known to affect the growth, height or weight <3rd percentile for age and sex, percent of ideal body weight >130%, and significant developmental delay or impairments, and did not have preexisting diagnosed gastrointestinal disorders or symptoms to suggest gastrointestinal, hepatic, or pancreatic disease. Both protocols were approved by the Committee for the Protection of Human Subjects of the institutional review board at CHOP, and at the subjects’ with CF respective home institutions. Written informed consent and age-appropriate assent were obtained from the parent/legal guardian and each subject, respectively. Subjects with CF were seen at the CHOP Clinical Translational Research Center (CTRC) for overnight admissions, while in their usual state of good health. Evaluations included clinical status, anthropometry, dietary (food and supplement) intake, and phlebotomy. Subjects with CF had home fecal collections and spirometry performed at the study visit. The healthy subjects had 1 assessment performed during a 1-day study visit.

Energy Intake

Seven-day home-based weighed food records were obtained from both groups after verbal and written instructions were provided along with measuring cups, spoons, and digital food scales. Research dietitians analyzed the diet records (Nutrition Data System, Minneapolis, MN). The details of the specific brands of nutritional supplements, frequency, and dose were recorded. Total grams of fat and energy in kilocalories (kcal) from fat, carbohydrates, and protein were calculated. Percent energy expenditure requirement (%EER) was calculate for age and sex for the “active range” of physical activity as previously determined for subjects with CF (16) as well as for the healthy comparison group participants.

Intake of total fat, SFA, MUFA, and PUFA; total ω 6 polyunsaturated fatty acid (Tω6PUFA:LA + AA); Tω3PUFA (ALA + DHA + eicosapentaenoic acid [EPA; 20:5ω3]); LA; ALA; AA; and DHA were reported in both grams per day and energy intake percent (%kcal). LA and ALA intake were also expressed as a function of the adequate intake level (AI) of the dietary reference intakes (DRI) (17). The ratios of SFA:PUFA, Tω6PUFA:Tω3PUFA, and LA:ALA were all calculated (g/d).

The group with CF received detailed instructions on collection and storage for home-based 3-day stool collections. The collection was analyzed for stool total fat content by the gravimetric method (Mayo Laboratories, Rochester, MN), and the coefficient of fat absorption (%CFA) was calculated as previously described (18). This determination of %CFA was made while study subjects were on their respective habitual regimens of pancreatic enzyme replacement therapy.

Serum FA Analysis

For the subjects with CF, fasting serum phospholipid FA concentrations were determined. A nonfasting serum phospholipid FA assessment from the healthy group participants was used for comparison. In a series of studies, no significant diurnal variation was found in serum phospholipid FA status (B. Strandvik, unpublished observation). After lipid extraction according to Folch et al (19), serum phospholipids were fractionated on a single SEP-PAK aminopropyl cartridge (Waters Corp, Milford, MA), and after hydrolysis and transmethylation the FA methyl esters were separated, identified, and quantitated by capillary gas-liquid chromatography as previously described (20). All values are expressed as molar percentage (mol%) of total serum phospholipid FA.

Body Composition, Growth, and Clinical Status

Height and weight were measured using standard techniques (21) with a stadiometer accurate to 0.1 cm (Holtain, Crymych, UK), and a digital scale accurate to 0.1 kg (Scaletronix, White Plains, NY). Height was adjusted for genetic potential (22) from measured or reported biological parent heights for the subjects with CF. Z scores for height (HAZ), adjusted height (adjHAZ), weight (WAZ), and body mass index (BMI; kg/m2, BMIZ) were computed (23). For the CF group, pulmonary function was evaluated by standard methods for spirometry (24,25) following inhaled albuterol and chest physiotherapy. FEV1 percent predicted was used as the measure of pulmonary function (26,27).

Statistical Methods

Issues of sample size and power were evaluated. With a sample size of 65 subjects with CF and 22 controls, and using a 2-group t test with a 0.05 2-sided significance level, there was 80% power to detect an effect size of 0.70 between the CF and the comparison group participants. For a multiple linear regression model that already includes 4 covariates (age, sex, %CFA, %EER) with a squared multiple correlation R2 of 0.25, a sample size of 65 subjects with CF had 80% power to detect, at the 0.05 level of significance, an increase in R2 ≥0.0832 owing to the inclusion of an additional covariate (ie, a dietary intake covariate).

Histograms and 1-sample Kolmogorov-Smirnov tests were used to examine the distribution of continuous variables. Means and standard deviations (SDs) were calculated for clinical characteristics separately for subjects with CF and healthy comparison group participants, and comparisons between these 2 groups characteristics measured on a continuous scale were made using 2-group t tests (Table 1) because all of these variables had normal distributions. Comparisons between the 2 groups on categorical characteristics (ie, sex) were made using Fisher exact tests or chi-square tests. Means and SDs were tabulated by group for selected serum FA variables (Table 2), and dietary intake variables (Table 3), and comparisons between the groups were made using 2-group t tests. Log-transformed data were used for skewed variables when the transformation normalized the distribution. In cases wherein the transformation did not normalize the distribution, Mann-Whitney U tests were used.

Baseline clinical characteristics of subjects with cystic fibrosis and pancreatic insufficiency and healthy control subjects*
Dietary intake per day as mean (SD [standard deviation]) or median [range]* in subjects with CF and PI and healthy control subjects
Selected serum fatty acid profiles (mol%) in subjects with CF and PI and control subjects*

Differences between sexes on serum FA and dietary intake outcomes were examined using 2 group t test or Mann-Whitney U test. Pearson or Spearman correlation coefficients between types of dietary fat intake and serum FA outcomes were computed. These correlations facilitated comparison with previously published studies (28,29).

Linear regression models were used to examine the ability of various dietary intake variables to predict various serum FA outcomes, controlling for age, sex, %CFA, and kcal. A hierarchical approach was used in which age, sex, %CFA, and total energy intakes were entered at step 1, and then the particular serum FA variable or dietary intake variable of interest was entered at step 2. Change in R2R2) owing to the addition of the serum FA variables or dietary predictors to the model already containing age, sex, %CFA, and total energy intake (kcal/d) was then determined.

Linear regression models were also used to examine the ability of various dietary intake variables to predict serum FA outcomes, using data from both groups (total of subjects with CF and the comparison group participants), while controlling for age, sex, %CFA, and kcal. For the comparison group participants, %CFA was not collected, and therefore values of %CFA in the normal range (ie, between 93 and 99%) were randomly assigned for these analyses. Group membership and interactions between Group and the other predictors were examined in these models.

Despite the many multiple regression models and tests of a significant increment in the R2 owing to the addition of 1 dietary predictor to a regression model already containing 4 covariates (ie, age, sex, %CFA, and energy intake), no adjustment to the level of significance was made; it was suggested that not making adjustments for multiplicity was preferable as it led to fewer errors of interpretation (30–32). Therefore, a P value of <0.05 was used to denote statistical significance, and all P values were reported to allow the reader to interpret the results (supplementary Table 1,


A total of 65 subjects with CF and PI (8.4 ± 1.0 years; 49% girls) and 22 healthy controls (8.5 ± 1.1 years; 59% girls) participated. There were no significant differences between the subjects with CF and the healthy controls with respect to age, sex, and growth status (Table 1). The subjects with CF had normal mean FEV1 of 98 ± 14% of predicted, and slightly impaired fat absorption, mean %CFA of 85 ± 11.

Dietary intake data are presented in Table 2. Among the dietary intake variables, LA (g/d), ALA (mg/d), ALA (%AI and %kcal), EPA (g/d and %kcal), DHA (g/d and %kcal), Tω6PUFA (g/d), and Tω3PUFA (g/d and %kcal) had skewed distributions in the CF group. In the comparison group, dietary EPAs (g/d and %kcal) were skewed. Logarithmic transformations normalized all of these distributions except for dietary EPA (g/d and %kcal) in the CF group. Median values are presented for the skewed data.

The subjects with CF had significantly higher mean %EER, total protein, and total fat (mostly in the form of SFA) intake than the comparison group participants. Similarly, total SFA, MUFA, and PUFA intake were also significantly higher for the subjects with CF than for the comparison group participants (g/d). Median LA, ALA, Tω6PUFA, and Tω3PUFA intake (g/d) were significantly higher in the subjects with CF as compared to the comparison group participants, whereas the opposite was true for the dietary LA:ALA and Tω6PUFA:Tω3PUFA ratios, respectively. On an energy intake basis, PUFA and LA intake were not different between the 2 groups. There were no significant differences between the 2 groups for the LCPUFA intake, that is, AA, DHA, and EPA.

Major serum phospholipid FA data are presented in Table 3. There were significant differences for serum FA status between the 2 groups. Serum SFA and MUFA were higher in the subjects with CF as compared to the comparison group participants, most likely reflecting the significantly higher intake because carbohydrate intake did not differ. PUFA were lower in the subjects with CF. Serum LA, AA, and DHA concentrations were lower, whereas ALA and eicosatrienoic (mead) acid (ETA) were significantly higher in the subjects with CF. Despite greater median dietary LA intake, median serum LA concentration was lower in the subjects with CF and 40% had LA ≤21 mol%. In a report of serum PUFA status and clinical outcomes involving the subjects with CF in the present study, this LA serum concentration cutoff point was shown to be associated with improved nutritional, growth, and pulmonary outcomes (10). Only 12% of the subjects with CF had LA concentrations >26 mol% (which is the most frequently used laboratory reference cutoff point value (10)). The T:T and AA:DHA ratios were also significantly higher in the subjects with CF; depending on the T:T cutoff point used, between 17% (T:T > 0.04 (33)) and 49% (T:T > 0.02) of the subjects with CF and none of the comparison subjects had EFAD.

In subjects with CF, age was negatively correlated with serum LA concentrations (Pearson r = −0.28, P = 0.025), and positively with myristic (14:0) acid (Pearson r = 0.32, P = 0.009, and palmitic (16:0) acid (Pearson r = 0.33, P = 0.007). A marginal, nonsignificant correlation was observed between age and serum palmitoleic (16:1w9) acid (Pearson r = 0.24, P = 0.057). Similarly, the correlation between age and serum T:T ratio was inconclusive (Spearman r = 0.24 [P = 0.058] and log-transformed T:T ratio Pearson r = 0.16 [P = 0.21]). These findings may suggest that EFAD is progressive with age.

In the comparison subjects, Pearson correlation coefficients indicated that age was positively correlated with a number of dietary intake variables, including total fat (g/d) (r = 0.66, P = 0.001), SFA (g/d) (r = 0.47, P = 0.028), MUFA (g/d) (r = 0.69, P < 0.0005), and trans fats (g/d) (r = 0.54, P = 0.009). No clear correlations were observed between age and PUFA intake (g/d), LA (g/d), ALA (mg), Tω6PUFA, AA (g/d), AA (%kcal), and serum concentrations of palmitic and palmitoleic acids. There was no correlation between age and serum ALA.

In the subjects with CF, differences between the sexes were observed in the serum T:T ratio, total intakes of fat (g/d), SFA (g/d), and MUFA (g/d) in favor of the boys (P < 0.05). In the comparison group, differences between the sexes were observed in serum DHA, with girls having statistically higher concentrations (P < 0.05).

Pearson and Spearman bivariate correlation coefficients between dietary fat intake and serum PUFA concentrations in CF subjects indicated an association between the LA intake (kcal) and LA serum concentrations (r = 0.25, P = 0.048). There was also an association between DHA intake after logarithmic transformation and DHA serum concentrations using Pearson correlations, DHAlog (g/d) with DHA in serum: r = 0.29, P = 0.020 and DHAlog (kcal) with DHA in serum: r = 0.35, P = 0.004.

Total fat intake (kcal) was positively associated with the serum LA (r = 0.253, P = 0.042) and negatively with serum ALA concentrations (r = −0.266, P = 0.032). SFA intake (grams) was negatively associated with serum ALA and AA concentrations (r = −0.245, P = 0.049, and r = −0.252, P = 0.043, respectively), and positively with the log-transformed serum T:T ratio (T:Tlog; r = 0.299, P = 0.015). The MUFA intake (kcal) was positively associated with serum LA and DHA concentrations (r = 0.266, P = 0.032, and r = 0.250, P = 0.045, respectively), and negatively with serum T:Tlog ratio (r = −0.252, P = 0.043). The PUFA intake (kcal) was negatively associated with T:Tlog ratio (r = −0.312, P = 0.011).

Regression model analyses of dietary intake predicting selected serum PUFA controlling for age, sex, kcal, and CFA% for the subjects with CF are presented in supplementary Table 1 ( Serum LA concentration was positively predicted by dietary total fat (Coeff = 0.070, standard error [SE] = 0.029, R2 = 0.266, ΔR2 = 0.077, P = 0.017), MUFA (Coeff = 0.176, SE = 0.080, R2 = 0.251, ΔR2 = 0.063, P = 0.033), PUFA (Coeff = 0.232, SE = 0.091, R2 = 0.271, ΔR2 = 0.082, P = 0.014), LA (Coeff = 0.234, SE = 0.096, R2 = 0.264, ΔR2 = 0.076, P = 0.018), ALA (Coeff = 2.408, SE = 0.945, R2 = 0.271 ΔR2 = 0.083, P = 0.014), and Tω6PUFA (Coeff = 0.233, SE = 0.096, R2 = 0.264, ΔR2 = 0.076, P = 0.018) intake. Serum DHA concentrations were positively predicted by dietary MUFA (Coeff = 0.031, SE = 0.014, R2 = 0.0.156, ΔR2 = 0.069, P = 0.035), ALA (Coeff = 0.544, SE = 0.164, R2 = 0.235, ΔR2 = 0.148, P = 0.002), and Tω3PUFAlog (Coeff = 0.781, SE = 0.236, R2 = 0.234, ΔR2 = 0.148, P = 0.002) intake. Serum T:T status was negatively predicted by total fat (Coeff = −0.012, SE = 0.006, R2 = 0.391, ΔR2 = 0.046, P = 0.043), MUFA (Coeff = −0.041, SE = 0.016, R2 = 0.409, ΔR2 = 0.064, P = 0.016), PUFA (Coeff = −0.044, SE = 0.019, R2 = 0.401, ΔR2 = 0.056, P = 0.024), LA (Coeff = −0.043, SE = 0.020, R2 = −0.394, ΔR2 = 0.048, P = 0.037), ALA (Coeff = −0.533, SE = 0.194, R2 = 0.422, ΔR2 = 0.076, P = 0.008), Tω6PUFA (Coeff = −0.043, SE = 0.020, R2 = 0.394 ΔR2 = 0.049, P = 0.037), and Tω3PUFAlog (Coeff = −0.446, SE = 0.184, R2 = 0.406, ΔR2 = 0.061, P = 0.018) intake. The serum AA:DHA ratio was negatively predicted by ALA (Coeff = −2.146, SE = 0.657, R2 = 0.194, ΔR2 = 0.151, P = 0.002) and Tω3PUFAlog (Coeff = −2.666, SE = 0.967, R2 = 0.155, ΔR2 = 0.113, P = 0.008) intake.

Type of dietary fat did not predict serum ALA, and DHA intake did not predict serum DHA status (data not shown). SFA intake did not predict any of the serum FA outcomes of clinical interest. LA intake did not predict serum AA concentration (data not shown). Dietary Tω6PUFA:Tω3PUFA did not predict any of the serum outcomes of interest (data not shown).

The effects of dietary predictors in models using data from both groups were generally similar to results from models that used data from CF subjects only (data not shown), with the exception of the dietary predictor MUFA for serum outcome of DHA, which was no longer statistically significant. There was a consistent statistically significant effect of sex and a statistically significant group-by-sex interaction effect for serum DHA outcome. There were no statistically significant group-by-dietary predictor interaction effects for any of the dietary predictors at any of the serum outcomes, after controlling for confounders, indicating that the observed effects of dietary predictor were not different for the 2 groups.


Despite higher energy and LA intake in the subjects with CF, their serum LA concentration was significantly lower than in the comparison group. Dietary fat composition, when adjusting for energy intake, stool energy losses, age- and sex-predicted serum PUFA status for the subjects with CF. Type of dietary fat intake predicted serum FA outcomes in both the subjects with CF and in the comparison subjects in a similar manner. These findings have not been previously reported in preadolescent children with CF and PI.

The PUFA of clinical interest in CF are LA, DHA, T:T, and AA:DHA ratios. LA concentration was shown to be associated with growth and lung function in pediatric subjects with CF (10–13), and is considered a more relevant EFA status marker than the T:T ratio (10). ALA has 2 known biological roles: to serve as an energy substrate, and as a precursor to ω3LCPUFA-EPA, and, to a lesser extent, of DHA. ω3LCPUFA have anti-inflammatory properties and decreased the neutrophilic leukotriene (LTB4/LTB5) inflammatory ratio in subjects with CF (34). DHA constitutes the denominator in the AA:DHA ratio, which is an inflammatory index elevated in CF nasal epithelium (35). Total fat intake has been demonstrated to be associated with improved clinical outcomes (14). Given that LA and DHA are described as the most consistently decreased PUFA in CF (7,9), and that they have clinical and biochemical importance, determining dietary influences on these serum PUFA concentration are relevant to clinical care.

The relationship between different types of dietary fat intake and serum or plasma PUFA status was investigated in Italian subjects (29) with CF of similar age and sex to those in the present study and in Spanish adult subjects with CF (28). Similar to the present study, the subjects in both of these European studies had higher total fat and energy intake than control subjects. In all of these studies, serum LA and DHA status were lower in the subjects with CF as compared to the respective control groups. There were no associations between type of dietary fat intake and serum LA and DHA in either of these prior studies (28,29). Specifically, dietary LA intake has been previously reported to influence serum LA status in infants with CF (12), as well as in children of 6 to 18 years with CF (11); logistic regression and multiple regression analyses were used, respectively, in these specific studies. The relationships between other types of dietary fats and serum LA and other FA of interest, however, were not reported.

Differences between results across these studies may also reflect additional dietary differences, complexities, and multiple influences on FA metabolism in CF.

In the present study, the rationale for controlling for age and sex in the regression models relate to previous findings that serum PUFA was associated with age and sex (10). Fat and energy are related variables and provided the rationale for controlling for energy intake and losses. Fecal fat excretion has been shown to be highly correlated with fecal energy losses (36), and was therefore included in the regression analyses. By controlling for energy variables in this manner, this statistical modeling allowed us to reduce potential confounding influences to type of dietary fat.

In the present study, total fat intake was associated with serum LA and inversely with the T:T ratio by both simple correlations and in the regression models, underlying its importance in CF. LA intake predicted serum LA status and negatively predicted the T:T ratio, but did not predict serum AA (data not shown) or the AA:DHA ratio.

Dietary ALA and Tω3PUFA intake influenced serum DHA concentration, whereas DHA intake did not, probably because of the extremely low intake of DHA. The efficiency of conversion of ALA to its ω3 LCPUFA products EPA and DHA is low, approximately 5% and 0.5%, respectively (37,38). ALA is consumed in gram amounts whereas DHA and EPA are consumed in milligrams in the typical US diet (39,40). As such, dietary ALA intake may also influence serum DHA concentration in the US population. ALA and Tω3PUFA intake also negatively predicted the AA:DHA ratio (specifically, by predicting higher DHA). Both LA and ALA intake negatively predicted the serum T:T ratio, which is consistent with what is known about their metabolism (41).

ALA intake also interestingly influenced LA concentration. There are 2 likely explanations for this finding. First, although ALA is a precursor for EPA and DHA, it also serves as an energy substrate, which may spare the use of LA as an energy substrate. Second, the Δ6 desaturase (rate limiting step in the pathways from precursor PUFA to their respective LCPUFA) demonstrates substrate preferentiality for ω3 > ω6 > ω9 PUFA. This substrate preferentiality for ALA over LA may inhibit elongation of LA to its respective LCPUFA, which may also explain the positive effect of dietary ALA on serum LA concentration. Similar enzymatic substrate preferentiality and pathway interactions have been suggested by supplementation of EPA and DHA that resulted in improved LA status in subjects with CF (42). Increasing the intake of specific fats such as ALA in individuals with CF may allow for the preservation of LCPUFA by both providing a substrate for energy and influencing the preservation of LA via mechanisms described above.

Supplementation studies conducted with LA and DHA in animal models and human subjects have demonstrated that individual FA supplementation improves serum or tissue concentrations of that particular FA (42–46). These single FA supplementation studies, however, seem to demonstrate less influence overall on clinical status. Nevertheless, a recent 1-year trial of a combination of dietary fat supplements (with EPA, DHA, LA, and γ-linolenic acid) in adults with CF improved not only serum LA, DHA, and decreased AA:DHA, but also improved lean body mass, FEV1, decreased respiratory exacerbations, days of antibiotic used, and inflammatory markers (47). Similar positive clinical results have not been obtained in the many recent ω3 LCPUFA supplementations in subjects with CF (48).

Modification of type of dietary fat intake may be a more practical and effective strategy improving serum PUFA concentrations than the use of supplements. Dietary ALA intake can be increased by consuming more flaxseed, walnut, and rapeseed or canola oils. Several brands of margarines are now frequently supplemented with flaxseed oil, ALA, and/or DHA for example, and can be encouraged as part of dietary intake. People with CF in particular may benefit from increasing intake of LA to compensate for increased turnover. LA can be derived from corn, safflower, and sunflower oils. Some food groups are rich in LA and ω3 (LC)PUFA, such as light tuna canned in oil, and may be of particular benefit to patients with CF (49).

In summary, beyond the prevention of EFA deficiency, the type of dietary fat intake influences serum FAs associated with clinically important outcomes and with inflammation. Further study is required to corroborate and expand on these findings and to determine the effect on clinical care.


1. Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 2004; 15:13–18.
2. Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984; 779:89–137.
3. Kuo PT, Huang NN, Bassett R. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J Pediatr 1962; 60:394–403.
4. Strandvik B. Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr Scand Suppl 1989; 363:58–63.discussion 63–5:58–63.
5. Strandvik B, Berg U, Kallner A, et al. Effect on renal function of essential fatty acid supplementation in cystic fibrosis. J Pediatr 1989; 115:242–250.
6. Strandvik B. Long chain fatty acid metabolism and essential fatty acid deficiency with special emphasis on cystic fibrosis. In: Polyunsaturated Fatty Acid in Human, Nutrition. New York: Raven Press; 1992:159–67.
7. Cawood AL, Carroll MP, Wootton SA, et al. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care 2005; 8:153–159.
8. Deleted in proof.
9. Coste TC, Armand M, Lebacq J, et al. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007; 40:511–520.
10. Maqbool A, Schall JI, Garcia-Espana JF, et al. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2008; 47:635–644.
11. Walkowiak J, Lisowska A, Blaszczynski M, et al. Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease. J Pediatr Gastroenterol Nutr 2007; 45:488–489.
12. Shoff SM, Ahn HY, Davis L, et al. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006; 117:391–400.
13. Lloyd-Still JD, Bibus DM, Powers CA, et al. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr 1996; 85:1426–1432.
14. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988; 41:583–591.
15. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246–259.
16. Trabulsi J, Ittenbach RF, Schall JI, et al. Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis. Am J Clin Nutr 2007; 85:144–151.
17. Institute of Medicine (U.S.). Panel on Macronutrients, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academies Press; 2005.
18. Cohen JR, Schall JI, Ittenbach RF, et al. Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 40:438–444.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226:497–509.
20. Gronowitz E, Mellstrom D, Strandvik B. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br J Nutr 2006; 95:1159–1165.
21. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL:Human Kinetics Books; 1988.
22. Himes JH, Roche AF, Thissen D, et al. Parent-specific adjustments for evaluation of recumbent length and stature of children. Pediatrics 1985; 75:304–313.
23. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000:1–27.
24. Morris AH, Intermountain Thoracic Society. Clinical Pulmonary Function Testing: A Manual of Uniform Laboratory Procedures. 2nd ed. Salt Lake City, UT: Intermountain Thoracic Society; 1984.
25. Gardner RM. Standardization of spirometry: a summary of recommendations from the American Thoracic Society. The 1987 update. Ann Intern Med 1988; 108:217–220.
26. Zapletal A, Šamánek M, Paul T. Lung Function in Children and Adolescents: Methods, Reference Values. Basel; New York: Karger; 1987.
27. Wang X, Dockery DW, Wypij D, et al. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993; 148:1502–1508.
28. Olveira G, Dorado A, Olveira C, et al. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br J Nutr 2006; 96:343–349.
29. Colombo C, Bennato V, Costantini D, et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes? J Pediatr Gastroenterol Nutr 2006; 43:660–665.
30. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316:1236–1238.
31. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1:43–46.
32. Savitz DA, Olshan AF. Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol 1995;142:904–8.
33. Holman RT. The ratio of trienoic:tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J Nutr 1960; 70:405–410.
34. Panchaud A, Sauty A, Kernen Y, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 2006; 25:418–427.
35. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560–569.
36. Chen AH, Innis SM, Davidson AG, et al. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005; 81:686–691.
37. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 2007; 32:619–634.
38. Brenna JT, Salem N Jr, Sinclair AJ, et al. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009; 80:85–91.
39. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71:179S–188S.
40. Otten JJ, Hellwig JP, Meyers LD. DRI, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC:National Academies Press; 2006.
41. Jones PJH, Kubow S, Maurice ES. Lipids, sterols, and their metabolites. Modern Nutrition in Health and Disease 10th ed.Philadelphia:Lippincot Williams & Wilkins; 2006. 92–122.
42. De Vizia B, Raia V, Spano C, et al. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J Parenter Enteral Nutr 2003; 27:52–57.
43. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981; 34:1–7.
44. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006; 22:36–46.
45. Van Biervliet S, Devos M, Delhaye T, et al. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008; 78:109–115.
46. Jumpsen JA, Brown NE, Thomson AB, et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros 2006; 5:77–84.
47. Olveira G, Olveira C, Acosta E, et al. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol 2010; 46:70–77.
48. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev 2011:CD002201.
49. Maqbool A, Strandvik B, Stallings VA. The skinny on tuna fat: health implications. Public Health Nutr 2011; 14:2049–2054.

α-linolenic acid; cystic fibrosis; diet; linoleic acid; docosahexaenoic acid fatty acids

Supplemental Digital Content

Copyright 2012 by ESPGHAN and NASPGHAN